Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multivalent Pneumococcal Vaccine - Formulation 3
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Multivalent Pneumococcal Vaccine - Formulation 3 is an investigational pneumococcal conjugate vaccine (PCV) developed by Pfizer. It is designed to expand serotype coverage beyond the 20 serotypes included in the currently licensed Prevnar 20 (20vPnC). The vaccine utilizes a conjugate platform where capsular polysaccharides from various *Streptococcus pneumoniae* serotypes are covalently linked to a carrier protein, such as CRM197. This conjugation transforms the T-cell independent polysaccharide antigens into T-cell dependent antigens, which are necessary for inducing robust immune responses, high-affinity antibodies, and immunological memory in adults. Formulation 3 is one of several candidates being evaluated in Phase 1/2 clinical trials (e.g., NCT05836922) to optimize the serotype composition and dosage for maximum safety and immunogenicity against invasive pneumococcal disease.
- Other names
- Pfizer next-generation pneumococcal conjugate vaccine candidate
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Multivalent Pneumococcal Vaccine - Formulation 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multivalent Pneumococcal Vaccine - Formulation 3.